Associated Genetic Biomarkers
SLAMF7 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials that contain SLAMF7 status as an inclusion criterion, 2 are phase 1 (1 open).
Trials with SLAMF7 status in the inclusion eligibility criteria most commonly target multiple myeloma .
The most frequent alteration to serve as an inclusion eligibility criterion is SLAMF7 Expression .
Cyclophosphamide, fludarabine, cs1-car t therapy, and chimeric antigen receptor t-cells are the most frequent therapies in trials with SLAMF7 as an inclusion criteria .
Significance of SLAMF7 in Diseases
Multiple Myeloma +
SLAMF7 is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain SLAMF7 status and multiple myeloma as inclusion criteria, 2 are phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.